基于生理药代动力学模型预测个体患者奥氮平暴露量
本研究构建并验证了奥氮平的生理药代动力学(PBPK)模型,通过创建14例患者的虚拟双胞胎预测其奥氮平暴露量,并与治疗药物监测(TDM)实测浓度比较。预测与实测谷浓度的R²在全队列为0.833,在7例有CYP2C8基因分型患者中为0.884;基于PBPK模型指导的剂量调整可使暴露变异降低两倍。
要点
- PBPK模型能准确预测健康高加索人、中国人和老年高加索人的奥氮平药代动力学参数。
- 虚拟双胞胎预测的奥氮平谷浓度与患者TDM实测值相关性良好(R²=0.833)。
- 基于PBPK模型指导的剂量调整可使奥氮平暴露变异系数从0.37降至0.18。
核心结论
- 利用PBPK建模与模拟可预测个体患者的奥氮平暴露量。
- 基于PBPK模型指导的剂量调整可降低奥氮平暴露的变异性。
研究设计与样本
- 在Simcyp®(V14.1)中构建奥氮平的自下而上PBPK模型,并用已有药代动力学研究和TDM数据验证。
- 将Simcyp®健康志愿者人群文件个体化,为14例患者创建虚拟双胞胎,比较预测暴露与实测浓度。
主要发现
- 单剂量研究药代动力学参数在健康高加索人(平均倍数误差MFE 0.68–1.14)、健康中国人(MFE 0.82–1.18)和老年高加索人(MFE 0.55–1.30)中预测准确。
- 虚拟人群与TDM数据库患者的奥氮平谷浓度累积频率图可比。
- 预测与实测谷浓度R²在全队列14例患者中为0.833,在7例有额外CYP2C8基因分型患者中为0.884。
- PBPK指导的剂量调整后暴露变异系数为0.18,固定剂量方案为0.37,前者低两倍。
临床怎么用
- PBPK建模与模拟可作为模型引导精准给药的选项,用于个体化预测奥氮平暴露和调整剂量。
局限性
- 需进一步研究以考察该方法的临床潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of the present study was to predict olanzapine (OLZ) exposure in individual patients using physiologically based pharmacokinetic modelling and simulation (PBPK M&S). METHODS: A 'bottom-up' PBPK model for OLZ was constructed in Simcyp® (V14.1) and validated against pharmacokinetic studies and data from therapeutic drug monitoring (TDM). The physiological, demographic and genetic attributes of the 'healthy volunteer population' file in Simcyp® were then individualized to create 'virtual twins' of 14 patients. The predicted systemic exposure of OLZ in virtual twins was compared with measured concentration in corresponding patients. Predicted exposures were used to calculate a hypothetical decrease in exposure variability after OLZ dose adjustment. RESULTS: The pharmacokinetic parameters of OLZ from single-dose studies were accurately predicted in healthy Caucasians [mean-fold errors (MFEs) ranged from 0.68 to 1.14], healthy Chinese (MFEs 0.82 to 1.18) and geriatric Caucasians (MFEs 0.55 to 1.30). Cumulative frequency plots of trough OLZ concentration were comparable between the virtual population and patients in a TDM database. After creating virtual twins in Simcyp®, the R2 values for predicted vs. observed trough OLZ concentrations were 0.833 for the full cohort of 14 patients and 0.884 for the 7 patients who had additional cytochrome P450 2C8 genotyping. The variability in OLZ exposure following hypothetical dose adjustment guided by PBPK M&S was twofold lower compared with a fixed-dose regimen - coefficient of variation values were 0.18 and 0.37, respectively. CONCLUSIONS: Olanzapine exposure in individual patients was predicted using PBPK M&S. Repurposing of available PBPK M&S platforms is an option for model-informed precision dosing and requires further study to examine clinical potential.
引用
- Polasek TM, Tucker GT, Sorich MJ, et al. Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. Br J Clin Pharmacol. 2018. PMID: 29194718. doi:10.1111/bcp.13480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。